Barinthus Biotherapeutics plc

BRNS · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Market Cap$47,611$141,644$87,533$413,170
- Cash$110,662$142,090$194,385$214,054
+ Debt$12,007$12,976$8,773$7,222
Enterprise Value-$51,044$12,530-$98,079$206,338
Revenue$14,969$802$44,703$268
% Growth1,766.5%-98.2%16,580.2%
Gross Profit$14,969$802$44,703$268
% Margin100%100%100%100%
EBITDA-$55,374-$71,065$5,192-$47,870
% Margin-369.9%-8,861%11.6%-17,861.9%
Net Income-$61,074-$73,347$5,342-$50,865
% Margin-408%-9,145.5%11.9%-18,979.5%
EPS Diluted-1.55-1.910.14-1.37
% Growth18.8%-1,464.3%110.2%
Operating Cash Flow-$28,940-$50,925-$14,431-$32,583
Capital Expenditures-$892-$5,413-$6,138-$1,146
Free Cash Flow-$29,832-$56,338-$20,569-$33,729
Barinthus Biotherapeutics plc (BRNS) Financial Statements & Key Stats | AlphaPilot